文献速递脑血管病

替奈普酶静脉溶栓治疗大血管闭塞患者的系统综述与荟萃分析

Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions: Systematic Review and Meta-Analysis.
PubMed 文献 · Stroke · 2020-12-04

该系统综述与荟萃分析纳入4项随机对照试验共433例大血管闭塞的急性缺血性卒中患者,比较替奈普酶与阿替普酶静脉溶栓的疗效与安全性。结果显示替奈普酶组3个月改良Rankin量表0-2分、成功再通及功能改善的几率均显著高于阿替普酶组,而早期神经改善、症状性颅内出血及死亡率无差异。

要点

  • 大血管闭塞患者替奈普酶静脉溶栓的3个月良好功能结局优于阿替普酶。
  • 替奈普酶与阿替普酶在症状性颅内出血和死亡率方面无显著差异。
  • 替奈普酶可提高成功再通率,支持其作为大血管闭塞静脉溶栓的选择。

核心结论

  • 大血管闭塞的急性缺血性卒中患者接受替奈普酶静脉溶栓,其再通和临床结局显著优于阿替普酶。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和Scopus,纳入4项随机对照试验共433例确诊大血管闭塞的急性缺血性卒中患者。

主要发现

  • 替奈普酶组3个月改良Rankin量表0-2分的比值比为2.06(95%CI 1.15-3.69)。
  • 替奈普酶组成功再通的比值比为3.05(95%CI 1.73-5.40)。
  • 替奈普酶组功能改善(改良Rankin量表所有等级各降1分)的共同比值比为1.84(95%CI 1.18-2.87)。
  • 上述结局的异质性低或无(I2≤20%)。
  • 早期神经改善、症状性颅内出血、任何颅内出血、改良Rankin量表0-1分及3个月全因死亡率在两组间无差异。

关键数值与推荐

  • 替奈普酶使用不同剂量,阿替普酶标准剂量为0.9 mg/kg。
  • 主要结局为3个月改良Rankin量表评分0-2分的比值比。

临床怎么用

  • 对于大血管闭塞的急性缺血性卒中患者,可考虑使用替奈普酶进行静脉溶栓以改善再通和功能结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Accumulating evidence from randomized controlled clinical trials suggests that tenecteplase may represent an effective treatment alternative to alteplase for acute ischemic stroke. In the present systematic review and meta-analysis, we sought to compare the efficacy and safety outcomes of intravenous tenecteplase to intravenous alteplase administration for acute ischemic stroke patients with large vessel occlusions (LVOs). METHODS: We searched MEDLINE (Medical Literature Analysis and Retrieval System Online) and Scopus for published randomized controlled clinical trials providing outcomes of acute ischemic stroke with confirmed LVO receiving intravenous thrombolysis with either tenecteplase at different doses or alteplase at a standard dose of 0.9 mg/kg. The primary outcome was the odds of modified Rankin Scale score of 0 to 2 at 3 months. RESULTS: We included 4 randomized controlled clinical trials including a total of 433 patients. Patients with confirmed LVO receiving tenecteplase had higher odds of modified Rankin Scale scores of 0 to 2 (odds ratio, 2.06 [95% CI, 1.15-3.69]), successful recanalization (odds ratio, 3.05 [95% CI, 1.73-5.40]), and functional improvement defined as 1-point decrease across all modified Rankin Scale grades (common odds ratio, 1.84 [95% CI, 1.18-2.87]) at 3 months compared with patients with confirmed LVO receiving alteplase. There was little or no heterogeneity between the results provided from included studies regarding the aforementioned outcomes (I2≤20%). No difference in the outcomes of early neurological improvement, symptomatic intracranial hemorrhage, any intracranial hemorrhage, and the rates of modified Rankin Scale score 0 to 1 or all-cause mortality at 3 months was detected between patients with LVO receiving intravenous thrombolysis with either tenecteplase or alteplase. CONCLUSIONS: Acute ischemic stroke patients with LVO receiving intravenous thrombolysis with tenecteplase have significantly better recanalization and clinical outcomes compared with patients receiving intravenous alteplase.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Katsanos AH, Safouris A, Sarraj A, et al. Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions: Systematic Review and Meta-Analysis. Stroke. 2020. PMID: 33272127. doi:10.1161/STROKEAHA.120.030220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。